GO:0070699 type II activin receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0070699 (type II activin receptor binding) is a molecular function describing the selective binding of a ligand or protein to a type II activin receptor (ActRIIA/ACVR2A or ActRIIB/ACVR2B).
• The type II activin receptor extracellular domain adopts a three-finger toxin fold, a structural feature that underlies ligand recognition.
• Blocking this binding interaction with antibodies or ligand traps produces strong skeletal muscle hypertrophy and protects against atrophy in preclinical models.
• The clinical candidate bimagrumab, a monoclonal antibody against activin type II receptors, is under investigation for obesity and metabolic disease.
• Small-molecule inhibitors such as SB-431542 target the downstream type I receptors ALK4/ALK5/ALK7 rather than the type II receptor binding event itself.
• Activin E signals specifically through ALK7, illustrating that type II receptor binding is a gateway to distinct downstream signaling outputs.
Description
GO:0070699, type II activin receptor binding, is a molecular function term that captures the physical interaction between a ligand or protein and a type II activin receptor, principally ACVR2A (ActRIIA) and ACVR2B (ActRIIB). This binding event is the first committed step in activin and related TGF-beta superfamily signaling, and it determines which downstream type I receptor and SMAD pathway will be engaged. Because the type II receptor is the shared entry point for multiple ligands, its binding properties are of central interest to researchers in muscle biology, metabolism, and oncology. The extracellular ligand-binding domain of the type II activin receptor was shown to adopt a three-finger toxin fold, providing a structural basis for how ligands are recognized. This structural insight, combined with functional studies using blocking antibodies, has made type II activin receptor binding a tractable target for therapeutic intervention. In this article we define the term, summarize its mechanism, list the key genes and proteins involved, and outline experimental models and methods for studying it.
type II activin receptor binding At A Glance
| GO ID | GO:0070699 |
|---|---|
| GO term | type II activin receptor binding |
| Ontology | molecular_function |
| Synonym | none |
| Definition | Binding to a type II activin receptor. |
| Major function | Mediates the initial recognition step between ligands and type II activin receptors, initiating downstream SMAD signaling. |
| Representative receptors | ACVR2A (ActRIIA) and ACVR2B (ActRIIB). |
| Structural feature | The extracellular ligand-binding domain adopts a three-finger toxin fold. |
| Therapeutic relevance | Blocking this binding with antibodies or ligand traps induces muscle hypertrophy and is being explored for obesity and metabolic disease. |
What Is GO:0070699?
According to the Gene Ontology, GO:0070699 (type II activin receptor binding) is defined as the binding to a type II activin receptor. In practical terms, it describes any molecular event in which a protein or ligand physically associates with a type II activin receptor, such as ACVR2A or ACVR2B, through non-covalent interactions. This function is distinct from binding to type I receptors, which are downstream partners in the signaling complex. The term is used to annotate gene products that directly contact the type II receptor, including natural ligands and engineered blocking proteins.
Why Is type II activin receptor binding Important in Cell Biology?
Type II activin receptor binding is important because it gates a broad range of TGF-beta superfamily signals that control muscle mass, metabolism, and cell growth. Antibodies that block this binding produce strong skeletal muscle hypertrophy and protect from atrophy, demonstrating that the interaction is functionally rate-limiting in vivo. The same interaction is being targeted clinically: bimagrumab, a monoclonal antibody against activin type II receptors, is under investigation for obesity and related metabolic conditions. Ligand traps targeting type II activin receptors are also being developed for clinical applications. Understanding the molecular details of this binding event is therefore essential for designing selective therapeutics and for interpreting genetic and pharmacological experiments.
• Controls skeletal muscle growth and atrophy through ActRIIA/ActRIIB-mediated signaling.
• Represents a validated therapeutic node for muscle-wasting conditions and metabolic disease.
• Determines which downstream type I receptor (ALK4/ALK5/ALK7) is engaged.
• Provides a structural paradigm for ligand recognition via a three-finger toxin fold.
• Is the target of clinical-stage antibodies such as bimagrumab.
• Is the target of ligand traps designed to sequester activin ligands.
• Links activin E signaling specifically to ALK7.
• Can be studied with small-molecule inhibitors that act downstream at type I receptors.
• Is relevant to cancer biology through TGF-beta superfamily signaling components.
• Offers a clear entry point for CRISPR-based functional dissection of receptor-ligand interactions.
Molecular Mechanism of type II activin receptor binding
Ligand recognition by the type II receptor ectodomain
In simple terms: The receptor grabs the ligand using a specialized outer domain.
The extracellular ligand-binding domain of the type II activin receptor adopts a three-finger toxin fold, a compact scaffold that presents the ligand-contact surface. This structural arrangement allows the receptor to recognize activin and related TGF-beta superfamily ligands with specificity. The binding event is the first step in assembling a signaling-competent receptor complex.
Receptor complex assembly and type I receptor recruitment
In simple terms: Once the ligand is bound, the receptor recruits a partner to pass the signal inside the cell.
After ligand engagement, the type II receptor recruits and activates type I receptors such as ALK4, ALK5, or ALK7. This step is required for downstream SMAD phosphorylation and transcriptional responses. Activin E, for example, signals specifically through ALK7, showing that the identity of the recruited type I receptor determines the biological output.
Pharmacological blockade of the binding interface
In simple terms: Antibodies can physically block the receptor so the ligand cannot bind.
Monoclonal antibodies directed against activin type II receptors block ligand binding and induce strong skeletal muscle hypertrophy in preclinical models. A dual anti-ActRIIA/IIB antibody is required to promote maximal muscle hypertrophy, indicating that both receptors contribute to the response. Bimagrumab, a human monoclonal antibody against activin type II receptors, has advanced into clinical investigation for obesity.
Ligand traps and soluble decoy strategies
In simple terms: Soluble decoys soak up the ligand before it can reach the receptor.
Ligand traps targeting activin type II receptors are being developed as clinical applications to sequester activin ligands and prevent receptor binding. These agents act upstream of the receptor complex and therefore inhibit the entire downstream signaling cascade. They complement antibody-based approaches that directly occupy the receptor binding site.
Downstream inhibition at type I receptors
In simple terms: Some drugs act one step later, on the receptor that passes the signal along.
Small-molecule inhibitors such as SB-431542 block the type I receptors ALK4, ALK5, and ALK7 rather than the type II binding event itself. These compounds are useful for dissecting which downstream pathway is responsible for a given biological effect. They also highlight that type II receptor binding is functionally coupled to type I receptor kinase activity.
Key Genes Involved in GO:0070699 type II activin receptor binding
The following genes and proteins are directly implicated in type II activin receptor binding and its downstream signaling.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ACVR2A | Encodes ActRIIA, a type II activin receptor that binds activin and related ligands. | Target of blocking antibodies that induce muscle hypertrophy. |
| ACVR2B | Encodes ActRIIB, a type II activin receptor that binds activin and related ligands. | Dual blockade of ActRIIA and ActRIIB is required for maximal muscle hypertrophy. |
| INHBA | Encodes activin A, a ligand that binds type II activin receptors. | Ligand whose sequestration by traps prevents receptor binding. |
| INHBB | Encodes activin B, a ligand in the activin family. | Relevant to ligand-trap pharmacology. |
| INHBE | Encodes activin E, a ligand that signals specifically through ALK7. | Used to study ligand-specific downstream signaling. |
| ACVR1B | Encodes ALK4, a type I receptor recruited after type II receptor binding. | Target of SB-431542 and related inhibitors. |
| ACVR1C | Encodes ALK7, a type I receptor engaged by activin E. | Defines a specific signaling branch downstream of type II binding. |
| TGFBR1 | Encodes ALK5, a type I receptor inhibited by SB-431542. | Used to dissect TGF-beta versus activin signaling. |
| MSTN | Encodes myostatin, a TGF-beta superfamily ligand that signals through type II activin receptors. | Central to muscle hypertrophy studies. |
| SMAD2 | Downstream effector phosphorylated after type II/type I receptor activation. | Readout of pathway activation. |
| SMAD3 | Downstream effector in the activin/TGF-beta signaling axis. | Readout of pathway activation. |
| SMAD4 | Common mediator SMAD required for transcriptional responses. | Used to assess pathway integrity. |
| FKBP12 | Immunophilin that regulates type I receptor kinase activity. | Modulates downstream signaling after receptor binding. |
| Bimagrumab target (ACVR2A/ACVR2B) | Human monoclonal antibody target for obesity and muscle indications. | Clinical-stage validation of the binding interface. |
| Ligand trap targets (ACVR2A/ACVR2B) | Soluble decoys that sequester activin ligands. | Clinical applications targeting the binding event. |
| Candidate genes in colorectal neoplasia | Genes identified by targeted sequencing in ulcerative colitis-associated neoplasia. | Illustrates disease context for TGF-beta superfamily components. |
How Is type II activin receptor binding Regulated?
Type II activin receptor binding is regulated at multiple levels. Ligand availability is controlled by secreted antagonists and ligand traps that sequester activins before they reach the receptor. At the receptor level, antibody blockade prevents ligand engagement and shifts the balance toward muscle hypertrophy. Downstream, the recruitment of specific type I receptors such as ALK4, ALK5, or ALK7 determines which SMAD branch is activated. Small-molecule inhibitors like SB-431542 can further modulate the pathway by blocking type I receptor kinase activity after the binding event. Together, these layers provide multiple points for experimental and therapeutic intervention.
type II activin receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ACVR2A | Muscle atrophy and hypertrophy | Knockout or blocking antibody in mouse muscle models |
| ACVR2B | Muscle hypertrophy and metabolic regulation | Dual knockout or antibody-treated models |
| INHBE | Ligand-specific signaling through ALK7 | Overexpression or knockout in cell-based assays |
| ACVR1C | Activin E signaling branch | Point-mutation or knockout models |
| Candidate genes in colorectal neoplasia | Ulcerative colitis-associated neoplasia | Targeted sequencing and functional validation |
Muscle atrophy and sarcopenia
Blocking type II activin receptor binding with antibodies induces strong skeletal muscle hypertrophy and protects from atrophy in preclinical models. Dual blockade of ActRIIA and ActRIIB is critical to promote maximal skeletal muscle hypertrophy, indicating that both receptors contribute to muscle mass regulation. These findings support the development of receptor-blocking agents for muscle-wasting conditions.
Obesity and metabolic disease
Bimagrumab, a human monoclonal antibody against activin type II receptors, is under investigation for treating obesity. By blocking ligand binding to the receptor, the antibody alters downstream signaling in a way that affects body composition. This represents a clinical translation of the type II activin receptor binding function.
Cancer and colorectal neoplasia
Targeted sequencing of candidate gene variants in ulcerative colitis-associated colorectal neoplasia has identified alterations in TGF-beta superfamily pathway components. Although the study focuses on candidate gene variants rather than type II receptor binding directly, it highlights the disease relevance of this signaling axis. Further work is needed to determine how specific binding events contribute to neoplasia.
Ligand-specific signaling in disease
Activin E signals specifically through ALK7, demonstrating that different ligands can engage distinct downstream branches after type II receptor binding. This ligand specificity has implications for designing therapeutics that target only a subset of activin responses. Ligand traps targeting type II activin receptors are being developed to exploit this biology clinically.
From type II activin receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of ACVR2A reduce ligand binding and signaling? | ACVR2A knockout cell line or animal model |
| Does dual loss of ACVR2A and ACVR2B enhance muscle hypertrophy? | Dual knockout or dual antibody treatment |
| Can a point mutation in the ligand-binding domain abolish binding? | Point-mutation knock-in of ACVR2A/ACVR2B |
| Can a tagged receptor be used to monitor binding dynamics? | Tagged knock-in of ACVR2A or ACVR2B |
| Does overexpression of activin E alter ALK7 signaling? | Overexpression of INHBE in cell models |
| Can ligand traps prevent receptor binding in vivo? | Ligand-trap administration in animal models |
How to Study the type II activin receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Surface plasmon resonance | Direct binding affinity to type II activin receptors | Characterizing ligand-receptor interactions |
| X-ray crystallography | Three-dimensional structure of the ligand-binding domain | Defining the three-finger toxin fold |
| Antibody blocking assays | Inhibition of ligand binding and downstream signaling | Testing therapeutic antibodies |
| Ligand-trap assays | Sequestration of activin ligands | Evaluating decoy receptor strategies |
| Small-molecule inhibition | Blockade of type I receptor kinases | Dissecting downstream signaling |
| SMAD phosphorylation assays | Activation of downstream effectors | Quantifying pathway activity |
| Targeted sequencing | Candidate gene variants in disease samples | Identifying pathway alterations in neoplasia |
Binding assays and structural biology
Direct binding assays and structural studies have revealed that the type II activin receptor extracellular domain adopts a three-finger toxin fold. These methods define the molecular interface and guide the design of blocking agents. They are essential for validating whether a candidate protein or antibody engages the receptor.
Antibody and ligand-trap functional assays
Blocking antibodies against type II activin receptors can be tested for their ability to induce muscle hypertrophy and protect from atrophy. Dual anti-ActRIIA/IIB antibodies are evaluated to determine whether maximal hypertrophy requires blockade of both receptors. Ligand traps are assessed for their capacity to sequester activins and prevent receptor binding.
Small-molecule inhibitor profiling
SB-431542 is a potent and specific inhibitor of ALK4, ALK5, and ALK7, and is used to dissect downstream signaling after type II receptor binding. Profiling such inhibitors helps distinguish type II receptor binding events from type I receptor kinase activity. These experiments are complementary to receptor-blocking approaches.
Ligand-specific signaling readouts
Activin E signaling through ALK7 provides a model for studying ligand-specific outputs after type II receptor binding. Readouts such as SMAD phosphorylation and transcriptional reporters can be used to quantify pathway activation. These methods help link binding events to specific biological outcomes.
How CRISPR Can Be Used to Study GO:0070699 type II activin receptor binding
Knockout
CRISPR knockout of ACVR2A or ACVR2B can eliminate type II activin receptor binding and reveal its contribution to downstream signaling. Dual knockout models are useful for testing whether both receptors are required for maximal muscle hypertrophy. These models provide a clean genetic background for comparing with antibody-based blockade.
Point Mutation
Point mutations in the ligand-binding domain of ACVR2A or ACVR2B can be introduced to disrupt specific contact residues identified by structural studies. Such mutants help determine which residues are essential for ligand recognition. They also allow separation of binding from downstream signaling.
Knock-in
Tagged knock-in of ACVR2A or ACVR2B enables real-time monitoring of receptor localization and binding dynamics. Knock-in of disease-associated variants can model how sequence changes affect receptor function. These models are valuable for linking genotype to binding phenotype.
Overexpression
Overexpression of ligands such as INHBE (activin E) can be used to study ligand-specific signaling through ALK7 after type II receptor binding. Overexpression of receptors or ligands can also sensitize cells to pathway activation. These models complement loss-of-function approaches.
How EDITGENE Supports type II activin receptor binding Research
Researchers studying type II activin receptor binding-related genes often need to determine whether a candidate gene is causally involved in ligand recognition, receptor complex assembly, or downstream signaling. EDITGENE provides CRISPR-based cell models and screening services to support this work.
Contact EDITGENE today to design your custom CRISPR model for type II activin receptor binding research.
Frequently Asked Questions About type II activin receptor binding
What is GO:0070699?
GO:0070699 is the Gene Ontology molecular function term for type II activin receptor binding, defined as binding to a type II activin receptor.
What genes are involved in type II activin receptor binding?
Key genes include ACVR2A and ACVR2B, which encode the type II activin receptors, as well as ligands such as INHBA, INHBB, and INHBE.
What is the function of type II activin receptor binding?
It mediates the initial recognition step between activin-family ligands and type II receptors, initiating downstream SMAD signaling.
Which receptors bind activin?
The type II activin receptors ACVR2A (ActRIIA) and ACVR2B (ActRIIB) bind activin and related ligands.
How is type II activin receptor binding blocked therapeutically?
Monoclonal antibodies and ligand traps can block or sequester ligands, preventing receptor binding and downstream signaling.
What is bimagrumab?
Bimagrumab is an investigational human monoclonal antibody against activin type II receptors being studied for obesity.
What structural fold does the type II activin receptor use?
The extracellular ligand-binding domain adopts a three-finger toxin fold.
Does activin E signal through type II activin receptors?
Activin E signals specifically through ALK7, a type I receptor engaged after type II receptor binding.
What inhibitors target the activin signaling pathway?
SB-431542 is a potent and specific inhibitor of ALK4, ALK5, and ALK7, acting downstream of type II receptor binding.
How can CRISPR be used to study type II activin receptor binding?
CRISPR knockout, point mutation, knock-in, and overexpression models can be used to dissect receptor-ligand interactions and downstream signaling.
Conclusion
GO:0070699 (type II activin receptor binding) is a molecular function that governs the first step of activin and related TGF-beta superfamily signaling. Its structural basis, a three-finger toxin fold in the receptor ectodomain, provides a framework for understanding ligand recognition. Blocking this interaction with antibodies or ligand traps produces strong biological effects, including muscle hypertrophy, and has led to clinical-stage candidates such as bimagrumab. Continued research using CRISPR models and functional assays will clarify how this binding event contributes to muscle, metabolic, and neoplastic diseases.
References
- 1. Lach-Trifilieff E et al.. 2014. An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy.. Mol Cell Biol 34(4):606-18 PMID: 24298022
- 2. Morvan F et al.. 2017. Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy.. Proc Natl Acad Sci U S A 114(47):12448-12453 PMID: 29109273
- 3. Kaur M et al.. 2024. Bimagrumab: an investigational human monoclonal antibody against activin type II receptors for treating obesity.. J Basic Clin Physiol Pharmacol 35(6):325-334 PMID: 39385353
- 4. Inman GJ et al.. 2002. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7.. Mol Pharmacol 62(1):65-74 PMID: 12065756
- 5. Greenwald J et al.. 1999. Three-finger toxin fold for the extracellular ligand-binding domain of the type II activin receptor serine kinase.. Nat Struct Biol 6(1):18-22 PMID: 9886286
- 6. Vestal KA et al.. 2024. Activin E is a transforming growth factor β ligand that signals specifically through activin receptor-like kinase 7.. Biochem J 481(7):547-564 PMID: 38533769
- 7. Tsuchida K. 2026. Clinical Applications of Ligand Traps Targeting Activin Type II Receptors.. Antiinflamm Antiallergy Agents Med Chem 25(2):73-78 PMID: 41487000
- 8. Chakrabarty S et al.. 2017. Targeted sequencing-based analyses of candidate gene variants in ulcerative colitis-associated colorectal neoplasia.. Br J Cancer 117(1):136-143 PMID: 28524162
